Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 27, 2018. The document serves as a transaction notification regarding the vesting of deferred investment awards for specific Persons Discharging Managerial Responsibilities (PDMRs). It does not contain general business updates or operational results.
Key Financial Metrics
The filing does not report company-wide revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific executive compensation transactions.
| Executive | Position | Transaction Date | Instrument | Volume (Notional Shares) | Price per Share | Cash Payment (Gross) |
|---|---|---|---|---|---|---|
| Ms. E. Walmsley | Chief Executive Officer | 2018-09-23 | Ordinary Shares | 10,075.600 | £15.314 | £154,279.74 |
| Mr. R. G. Connor | President, Global Vaccines | 2018-09-23 | Ordinary Shares | 8,060.480 | £15.314 | £123,438.19 |
| Mr. D. S. Redfern | Chief Strategy Officer | 2018-09-23 | Ordinary Shares | 8,060.480 | £15.314 | £123,438.19 |
| Ms. C. Thomas | SVP, Human Resources | 2018-09-23 | Ordinary Shares | 8,060.480 | £15.314 | £123,438.19 |
Note: All payments are subject to applicable tax withholding. The transactions relate to the vesting of 25% of awards made on June 12, 2014, under the GlaxoSmithKline Deferred Investment Award Plan.
Material Changes
The filing does not provide comparative financial data or material changes to the company's financial position versus prior periods. The only change reported is the execution of these specific equity-based compensation vesting events.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on strategy, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of insider transactions.
Investor Verification Checklist
- Verify the total cash payout amounts for the named executives after tax withholdings.
- Confirm the share price of £15.314 aligns with the market price on September 23, 2018.
- Review the original award terms from June 12, 2014, to understand the vesting schedule.
- Check subsequent filings for any sales of shares by these executives following the cash settlement.